Minimal Benzodiazepine Exposure May Up Dementia Risk

Share this content:
Minimal Benzodiazepine Exposure May Up Dementia Risk
Minimal Benzodiazepine Exposure May Up Dementia Risk

THURSDAY, Feb. 4, 2016 (HealthDay News) -- Patients with minimal exposure to benzodiazepine have a slightly increased risk of dementia, according to a study published online Feb. 2 in The BMJ.

Shelly L. Gray, Pharm.D., from the University of Washington in Seattle, and colleagues conducted a prospective population-based cohort study involving 3,434 participants aged 65 years and older without dementia at study entry. The authors administered the cognitive screening instrument every two years to screen for dementia and assess cognitive trajectory. Computerized pharmacy data were used to identify benzodiazepine exposure, which consisted of the total standardized daily doses (TSDDs) dispensed over a 10-year period.

The researchers found that 23.2 percent of participants (797 participants) developed dementia over a mean follow-up of 7.3 years, of whom 637 developed Alzheimer's disease. For cumulative benzodiazepine use of one to 30, 31 to 120, and ≥121 TSDDs versus non-use, the hazard ratios for dementia were 1.25 (95 percent confidence interval [CI], 1.03 to 1.51), 1.31 (95 percent CI, 1.00 to 1.71), and 1.07 (95 percent CI, 0.82 to 1.39), respectively. Similar results were seen for Alzheimer's disease. There was no correlation for higher benzodiazepine use with more rapid cognitive decline.

"The risk of dementia is slightly higher in people with minimal exposure to benzodiazepines but not with the highest level of exposure," the authors write. "These results do not support a causal association between benzodiazepine use and dementia."

One author disclosed financial ties to UpToDate; one author disclosed financial ties to the pharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths